文献速递血栓与止血浆细胞疾病

蛋白酶体抑制剂卡非佐米对内皮细胞发挥抗炎和抗血栓作用

The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium.
PubMed 文献 · J Thromb Haemost · 2024-04-10

本研究以人脐静脉内皮细胞(HUVECs)为对象,观察卡非佐米(CFZ)对内质网应激、炎症和血栓标志物的影响。CFZ未诱导HUVECs内质网应激,反而上调Kruppel样因子4、内皮型一氧化氮合酶、组织型纤溶酶原激活物和血栓调节蛋白表达,减少TNFα介导的细胞间黏附分子1和组织因子表达,并抑制VWF-血小板串形成及VWF和血管生成素-2外排。

要点

  • CFZ未在汇合静息HUVECs中诱导内质网应激。
  • CFZ上调Kruppel样因子4、内皮型一氧化氮合酶、组织型纤溶酶原激活物和血栓调节蛋白表达。
  • CFZ减少TNFα介导的细胞间黏附分子1和组织因子表达,并抑制VWF-血小板串形成。

核心结论

  • CFZ不能诱导汇合静息内皮细胞的内质网应激,反而可减弱TNFα对内皮的促血栓作用。
  • 本研究提示CFZ不负面改变HUVECs,内皮蛋白酶体抑制可能为预防血栓提供潜在途径。

研究设计与样本

  • 体外研究:用人脐静脉内皮细胞(HUVECs)经CFZ处理,检测并功能评估内质网应激、炎症和血栓相关标志物。

主要发现

  • CFZ未诱导HUVECs内质网应激,但诱导Kruppel样因子4、内皮型一氧化氮合酶、组织型纤溶酶原激活物和血栓调节蛋白表达。
  • CFZ减少TNFα介导的细胞间黏附分子1和组织因子表达。
  • CFZ减少剪切应力下白细胞黏附,并减少TNFα处理后内皮上因子Xa生成和纤维蛋白凝块形成。
  • CFZ抑制Weibel-Palade小体中von Willebrand因子(VWF)和血管生成素-2的外排,并抑制VWF-血小板串形成。
  • 骨髓瘤细胞系来源培养基诱导VWF释放,该过程也被CFZ抑制。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carfilzomib (CFZ) is a second-generation proteasome inhibitor used to treat multiple myeloma. Potent inhibition of the proteasome results in chronic proteotoxic endoplasmic reticulum (ER) stress, leading to apoptosis. While CFZ has improved survival rates in multiple myeloma, it is associated with an increased risk of cardiovascular adverse effects. While this has been putatively linked to cardiotoxicity, CFZ could potentially also exhibit adverse effects on the endothelium. OBJECTIVES: To investigate the effects of CFZ on the endothelium. METHODS: Human umbilical vein endothelial cells (HUVECs) were treated with CFZ, and expression of relevant markers of ER stress, inflammation, and thrombosis was measured and functionally assessed. RESULTS: CFZ failed to induce ER stress in HUVECs but induced the expression of Kruppel-like factor 4, endothelial nitric oxide synthase, tissue plasminogen activator, and thrombomodulin and reduced tumor necrosis factor alpha (TNFα)-mediated intercellular adhesion molecule 1 and tissue factor expression, suggesting a potential protective effect on the endothelium. Consistent with these observations, CFZ reduced leukocyte adhesion under shear stress and reduced factor Xa generation and fibrin clot formation on the endothelium following TNFα treatment and inhibited von Willebrand factor (VWF) and angiopoietin-2 exocytosis from Weibel-Palade bodies. Subsequently, CFZ inhibited the formation of VWF-platelet strings, and moreover, media derived from myeloma cell lines induced VWF release, a process also inhibited by CFZ. CONCLUSION: These data demonstrate that CFZ is unable to induce ER stress in confluent resting endothelial cells and can conversely attenuate the prothrombotic effects of TNFα on the endothelium. This study suggests that CFZ does not negatively alter HUVECs, and proteasome inhibition of the endothelium may offer a potential way to prevent thrombosis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hjazi A, Maroto CG, Rodriguez-Gutierrez ME, et al. The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium. J Thromb Haemost. 2024. PMID: 38608731. doi:10.1016/j.jtha.2024.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。